Stopping GLP‑1s Raises Cardiovascular Risk

A BMJ Medicine study of 333,000 U.S. veterans with type‑2 diabetes found pausing GLP‑1 therapy for as little as six months increased heart attack and stroke risk, with up to a 22% higher risk after two years off the drug; restarting restored only part of the protection. The author argues adherence should be treated as a primary clinical outcome and that GLP‑1 prescriptions may imply long‑term or indefinite treatment commitments. — If true broadly, the finding shifts debates over GLP‑1 access, insurance coverage, informed consent, and long‑term care planning because stopping treatment is not just a cosmetic or weight‑regain issue but a cardiovascular risk issue.